Nuvasive Logo

30 Sep NuVasive to Sponsor and Participate at Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum ’22

Posted at 09:07h in News by
0 Likes

SAN DIEGO, Sept. 26, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Society for Minimally Invasive Spine Surgery (SMISS) as a sponsor and will attend the SMISS Annual Forum ’22 held September 29 to October 1, 2022 in Las Vegas.

“SMISS and NuVasive share a common belief in the importance of research and education to advance less invasive surgery,” said Chris Barry, chief executive officer at NuVasive. “With multiple approaches to enable patient-specific, optimized surgical outcomes, it is important to select the right procedure, create a patient-specific surgical plan, and utilize enabling technologies for more intelligent surgery. We look forward to showcasing our clinically backed X360 portfolio, enabled by Pulse®, at SMISS.”

Visit booth #201/203 for live demonstrations of Pulse and conversations with NuVasive leadership around X360 and thoracolumbar posterior procedural solutions. NuVasive will name the Pioneer in Lateral Access Award recipient during the SOLAS session on Thursday, September 29.

About NuVasive


NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company’s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements


NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. 

SOURCE: NuVasive, Inc., PR Newswire, September 26 2022.

To find out more news from the industry head over to our news section – orthocg.com/news